- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02341391
Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis
A Dose-escalating, Single-center, Phase I Clinical Trial to Investigate the Safety and Biological Efficacy of TissueGene-C in Degenerative Arthritis Patients.
The primary purpose of the this study is to evaluate the safety of TissueGene-C, a gene therapy product that uses allogenic human chondrocytes expressing Transforming Growth Factor(TGF)-β1 by assessing the inflammation at the injection site, the incidence and severity of the adverse events, the physical examination findings, and the laboratory test results after the intra-articular injection of TissueGene-C.
And Secondary purpose is to evaluate the biological efficacy (knee pain, range of motion, functional tests, and MRI) of TissueGene-C and the distribution of TissueGene-C outside the injection site.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
TissueGene-C is a biological new drug which consists of normal chondrocyte cells and transduced chondrocyte cells that express growth factor to modify osteoarthritis symptom for long term period.
During clinical trial Phase 1, we compare three different dose levels of TisssueGene-C in 6 months with 12 outpatients with degenerative arthritis. The patients are randomized by three different dose levels of TisssueGene-C in 1:1:1 ratio, and they are monitored and recorded for alleviating symptoms, sports activities, function of the knee, and the presence of adverse events.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Seoul, Korea, Republik von, 135-710
- Samsung Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female patients
- Patients aged 45 years or more with Grade IV [based on the International Cartilage Repair Society(ICRS) evaluation criteria from the MRI scan results] degenerative arthritis of the knee, whose symptoms had not been relieved by the conventional symptomatic treatment
- Healthy, with no major physical examination, hematology, serum chemistry, and urine test findings and no significant medical history
- Patients with cartilage damage sized 2-6 cm2 (based on the ICRS evaluation criteria from the MRI scan results)
- Voluntarily agreed to participate in this study and signed the informed consent form
Exclusion Criteria:
- Showed clinically significant hematology, serum chemistry, or urine test results at the screening visit
- Took an anti-inflammatory medication (prescribed or over-the-counter), including natural medicine, within 14 days from the administration of the investigational product
- Has a history of drug abuse within one year from the enrollment, or the urine test or blood alcohol test result was positive at the screening visit
- Received any injection in the target knee within two months before the initiation of the study
- Pregnant or breastfeeding female
- With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or the tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, and synovial chondromas)
- With an infectious disease, including HIV or hepatitis (HBV/HCV)
With a history any of the following clinically significant diseases:
- heart disease [e.g., myocardial infarction, arrhythmia, other serious heart disease, coronary artery bypass graft (CABG)]
- kidney disease (e.g., chronic renal failure, glomerulonephritis)
- liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)
- endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)
- insulin-dependent diabetes mellitus
medical history of or current malignant tumor In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests
- Leukemia : White Blood Cell level in the hematology
- Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma : Alkaline phosphatase level in the hematology
- Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study
- Showed positive drug test results at the screening visit
- Did not agree to use a contraceptive method (male and female)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: TissueGene-C(Low dose)
Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
|
3.0 x 10^6 cells
|
Experimental: TissueGene-C(Medium dose)
Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
|
1.0 x 10^7 cells
|
Experimental: TissueGene-C(High dose)
Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
|
3.0 x 10^7 cells
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants with Adverse Events after the administration of TissueGene-C
Zeitfenster: 6 months
|
Number of Participants with Adverse Events after the administration of TissueGene-C
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Changes in MRI scan
Zeitfenster: before and 28 days, 3 months, and 6 months
|
Change in the MRI scan results after the administration of TissueGene-C
|
before and 28 days, 3 months, and 6 months
|
Change in the Knee Society Clinical Rating System(KSCRS) test results
Zeitfenster: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Comparative Evaluation of knee exam
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Changes in WOMAC scores
Zeitfenster: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities(WOMAC)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Changes in 100 mm-VAS
Zeitfenster: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Analysis of the TGF-β1 expression using Enzyme-linked Immunosorbent Assay(ELISA) and Polymerase Chain Reaction(PCR)
Zeitfenster: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Analysis of the TGF-β1 expression using Enzyme-linked Immunosorbent Assay(ELISA) and Polymerase Chain Reaction(PCR)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Replication-competent retrovirus test (RCR test)
Zeitfenster: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Replication-competent retrovirus test (RCR test)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TGC-KI-01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Degenerative Arthritis
-
Smith & Nephew, Inc.Aktiv, nicht rekrutierendArthritis, degenerativSüdafrika
-
University Hospital, Basel, SwitzerlandRekrutierungHüftgelenk | Arthritis, degenerativSchweiz
-
Smith & Nephew, Inc.BeendetArthrose, Hüfte | Arthritis, degenerativAustralien
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterUnbekanntArthropathie des Knies | Arthritis, degenerativ | Arthritis-KnieVereinigte Staaten
-
Russian Academy of Medical SciencesAbgeschlossenArthrose | Gelenkerkrankung | Arthritis, degenerativ | Arthrose | Osteoarthrosis deformans | Arthrose, KnieRussische Föderation
-
US Department of Veterans AffairsUniversity of PittsburghAbgeschlossenArthrose | Arthrose, Knie | Arthrose, Hüfte | Arthritis, degenerativVereinigte Staaten
-
Haukeland University HospitalUniversity of Bergen; Haugesund Rheumatism HospitalAktiv, nicht rekrutierendOsteoarthritis Knie | Arthritis, degenerativNorwegen
-
VA Office of Research and DevelopmentAbgeschlossenArthrose, degenerativVereinigte Staaten
-
Renew Center, San Antonio, TexasAbgeschlossen
-
CDA Research Group, Inc.Abgeschlossen
Klinische Studien zur TissueGene-C(Low dose)
-
Hospital Universitario Ramon y CajalBeendet
-
GNT PharmaUnbekanntIschämischer SchlaganfallKorea, Republik von
-
Institute of Health Information and Statistics...Centre of Cardiovascular and Transplantation Surgery, Czech Republic; The Central... und andere MitarbeiterRekrutierungFamiliäre HypercholesterinämieTschechien
-
Assiut UniversityNoch keine Rekrutierung
-
Medicines Development for Global HealthImperial College London; Phillip T. and Susan M. Ragon FoundationBeendetHIV-InfektionenVereinigtes Königreich
-
Insel Gruppe AG, University Hospital BernThe Hospital for Sick Children; Children's Hospital of Philadelphia; Charite University... und andere MitarbeiterRekrutierungAtemwegsmanagementSchweiz, Kanada, Deutschland
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)Abgeschlossen
-
AmgenAbgeschlossenHypercholesterinämieFrankreich, Deutschland, Vereinigte Staaten, Tschechien, Italien, Australien, Spanien, Vereinigtes Königreich
-
Soovu Labs Inc.University of Washington; Northern California Research CorporationAbgeschlossenSchmerzen im unteren Rücken | Chronischer Schmerz | Analgesie | HitzeVereinigte Staaten
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AbgeschlossenMultiples Myelom und Plasmazell-NeoplasmaVereinigte Staaten